Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Cash from Financing Activities of $8.5 million for Q4 2025, down 28.39% on a QoQ basis from $11.9 million in Q2 2025, and up 11001.54% year-over-year from N/an in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $8.5 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 11001.54% year-over-year to $8.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.6 million (changed N/A YoY) and the FY2025 annual result came in at $20.6 million, up 6215.26% from the prior year.
- Cash from Financing Activities was $8.5 million for Q4 2025 at Apimeds Pharmaceuticals US, down from $11.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $11.9 million in Q2 2025 and bottomed at $76500.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 8.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.49 Mn |
| Dec 31, 2025 | 8.49 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 267,200.00 |
| Mar 31, 2025 | 267,200.00 |
| Dec 31, 2024 | 76,500.00 |
| Dec 31, 2024 | 76,500.00 |
| Sep 30, 2024 | 150,000.00 |
| Sep 30, 2024 | 150,000.00 |